Varenicline enhances dopamine release facilitation more than nicotine after long‐term nicotine treatment and withdrawal
Open Access
- 16 December 2014
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 3 (1) , e00105
Abstract
An important factor contributing to the high relapse rates among smokers is nicotine withdrawal symptoms. Multiple studies suggest that decreased dopamine release in nucleus accumbens plays a key role in withdrawal. However, recent reports showed that long‐term nicotine exposure itself also decreases accumbal dopamine release, suggesting that additional mechanisms are involved in withdrawal. Here, we used real‐time cyclic voltammetry in brain slices containing the nucleus accumbens to further elucidate the changes in dopamine release linked to nicotine withdrawal. Rats received vehicle or nicotine via the drinking water for 2–3 months. Studies assessing the expression of somatic signs in vehicle‐treated, nicotine‐treated, and 24‐h nicotine withdrawn rats showed that nicotine withdrawal led to a significant increase in somatic signs. Subsequent voltammetry studies showed that long‐term nicotine decreased single‐pulse‐stimulated dopamine release via an interaction at α6β2* receptors. Nicotine withdrawal led to a partial recovery in α6β2* receptor‐mediated release. In addition, long‐term nicotine treatment alone increased dopamine release paired‐pulse ratios and this was partially reversed with nicotine removal. We then evaluated the effect of bath‐applied nicotine and varenicline on dopamine release. Nicotine and varenicline both decreased single‐pulse‐stimulated release in vehicle‐treated, nicotine‐treated, and nicotine withdrawn rats. However, bath‐applied varenicline increased paired‐pulse ratios to a greater extent than nicotine during long‐term nicotine treatment and after its withdrawal. Altogether these data suggest that nicotine withdrawal is associated with a partial restoration of dopamine release measures to control levels and that varenicline's differential modulation of dopamine release may contribute to its mechanism of action.Keywords
Funding Information
- National Institutes of Health (NS 59910, GM103801, GM48677)
- California Tobacco Related Disease Research Program (17RT-0119)
This publication has 64 references indexed in Scilit:
- Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in ratsPharmacology Biochemistry and Behavior, 2012
- Withdrawal from Chronic Nicotine Exposure Alters Dopamine Signaling Dynamics in the Nucleus AccumbensBiological Psychiatry, 2012
- Dopamine release in the basal gangliaNeuroscience, 2011
- Acute in vivo nicotine administration enhances synchrony among dopamine neuronsBiochemical Pharmacology, 2011
- Nicotine-Mediated Activation of Dopaminergic Neurons in Distinct Regions of the Ventral Tegmental AreaNeuropsychopharmacology, 2011
- Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid systemNeuroscience & Biobehavioral Reviews, 2010
- Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptorsNeuropharmacology, 2010
- Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addictionTrends in Neurosciences, 2009
- Nicotine withdrawal produces a decrease in extracellular levels of dopamine in the nucleus accumbens that is lower in adolescent versus adult male ratsSynapse, 2009
- It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and moodProgress in Neurobiology, 2008